Monopar Therapeutics (NASDAQ:MNPR) Given New $85.00 Price Target at Chardan Capital

Monopar Therapeutics (NASDAQ:MNPR) had its price target boosted by equities research analysts at Chardan Capital from $60.00 to $85.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Chardan Capital’s price target indicates a potential upside of 16.37% from the company’s previous close.

Several other research firms also recently issued reports on MNPR. HC Wainwright assumed coverage on Monopar Therapeutics in a research note on Tuesday, August 26th. They issued a “buy” rating and a $70.00 price objective for the company. Oppenheimer assumed coverage on Monopar Therapeutics in a research note on Wednesday, September 3rd. They issued an “outperform” rating and a $77.00 price objective for the company. Lake Street Capital assumed coverage on Monopar Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $106.00 price objective for the company. BTIG Research upped their price objective on Monopar Therapeutics from $87.00 to $104.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $74.00 price objective on shares of Monopar Therapeutics in a research note on Wednesday, August 27th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Monopar Therapeutics has an average rating of “Buy” and an average target price of $80.22.

Monopar Therapeutics Trading Up 7.9%

MNPR stock opened at $73.04 on Thursday. The stock has a market capitalization of $450.66 million, a P/E ratio of -21.93 and a beta of 1.20. Monopar Therapeutics has a 12 month low of $4.12 and a 12 month high of $74.00. The firm has a 50-day moving average price of $43.25 and a 200-day moving average price of $38.70.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.12. As a group, equities analysts predict that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Insider Buying and Selling at Monopar Therapeutics

In other news, Director Christopher M. Starr sold 16,800 shares of the firm’s stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $40.00, for a total transaction of $672,000.00. Following the completion of the sale, the director owned 5,173 shares of the company’s stock, valued at $206,920. This trade represents a 76.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Kim R. Tsuchimoto sold 8,904 shares of the firm’s stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $356,160.00. Following the sale, the director directly owned 11,486 shares of the company’s stock, valued at approximately $459,440. This trade represents a 43.67% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 42,504 shares of company stock valued at $1,700,160. 20.50% of the stock is currently owned by company insiders.

Institutional Trading of Monopar Therapeutics

Several large investors have recently modified their holdings of MNPR. Affinity Asset Advisors LLC acquired a new stake in shares of Monopar Therapeutics during the 1st quarter worth approximately $2,257,000. Geode Capital Management LLC grew its position in shares of Monopar Therapeutics by 99.7% during the 2nd quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock worth $3,468,000 after buying an additional 48,379 shares during the period. Goldman Sachs Group Inc. acquired a new stake in shares of Monopar Therapeutics during the 1st quarter worth approximately $673,000. Jane Street Group LLC acquired a new stake in shares of Monopar Therapeutics during the 1st quarter worth approximately $377,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of Monopar Therapeutics during the 1st quarter worth approximately $328,000. Institutional investors and hedge funds own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.